Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 January 2015Website:
http://www.pieris.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 21:19:03 GMTDividend
Analysts recommendations
Institutional Ownership
PIRS Latest News
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
NEW YORK , Aug. 16, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK , Aug. 14, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kellanova (NYSE: K)'s sale to Mars, Incorporated for $83.50 per share in cash. If you are a Kellanova shareholder, click here to learn more about your legal rights and options.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceutical s , Inc. ( Nasdaq : PIRS ) , relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
What type of business is Pieris Pharmaceuticals?
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
What sector is Pieris Pharmaceuticals in?
Pieris Pharmaceuticals is in the Healthcare sector
What industry is Pieris Pharmaceuticals in?
Pieris Pharmaceuticals is in the Biotechnology industry
What country is Pieris Pharmaceuticals from?
Pieris Pharmaceuticals is headquartered in United States
When did Pieris Pharmaceuticals go public?
Pieris Pharmaceuticals initial public offering (IPO) was on 02 January 2015
What is Pieris Pharmaceuticals website?
https://www.pieris.com
Is Pieris Pharmaceuticals in the S&P 500?
No, Pieris Pharmaceuticals is not included in the S&P 500 index
Is Pieris Pharmaceuticals in the NASDAQ 100?
No, Pieris Pharmaceuticals is not included in the NASDAQ 100 index
Is Pieris Pharmaceuticals in the Dow Jones?
No, Pieris Pharmaceuticals is not included in the Dow Jones index
When was Pieris Pharmaceuticals the previous earnings report?
No data
When does Pieris Pharmaceuticals earnings report?
The next expected earnings date for Pieris Pharmaceuticals is 14 November 2024